Lubna Mirza, MD
Endocrinology, Diabetes & Metabolism · Norman, OKNPI 1326208513
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,448 of the $12,223 with a category attached, or 77.3%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 447 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- Tandem Diabetes Care, Inc.$1K
- Novo Nordisk$973
- AstraZeneca$837
- Lilly USA, LLC$808
- Amgen$729
- plus $5K from 45 others
Across 1,325 payments — averaging $622.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$540K
- Kowa Research Institute, Inc.$157K
- AbbVie$77K
- Sanofi US Services Inc.$37K
- AstraZeneca$9K
- Astrazeneca UK Limited$4K
What the payments were for
- Speaking & faculty fees$9508%
- Travel & lodging$1,78215%
- Food & beverage$9,44877%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,223 in reported general payments places this provider in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $472,957 |
| OzempicSemaglutide | 87 | $146,550 |
| MounjaroTirzepatide | 72 | $115,191 |
| TrulicityDulaglutide | 59 | $96,449 |
| JardianceEmpagliflozin | 63 | $86,742 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $69,020 |
| ForteoTeriparatide | 13 | $55,769 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $41,271 |
| ProliaDenosumab | 19 | $32,975 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 18 | $30,304 |
| Teriparatide | 13 | $30,045 |
| FarxigaDapagliflozin Propanediol | 16 | $17,106 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $14,478 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $12,435 |
| Xigduo XrDapaglifloz Propaned/Metformin | 25 | $12,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $382 | $472,95714 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $808 | $270,999155 claims |
| Novo NordiskOzempic | $973 | $146,55087 claims |
| Boehringer IngelheimJardiance | $133 | $86,74263 claims |
| AmgenProlia | $729 | $32,97519 claims |
| AstraZenecaFarxiga | $837 | $17,10616 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $5,870601 claims |
| AbbVieSynthroid | $269 | $5,84365 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Norman
- Tan PhamNorman$7K
- Shelley McClureNorman$3K
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Matthew DraelosEdmond$110K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.